Aktie 300957 YUNNAN BOTANEE BIO-TECHNOLOGY GROUP CO.LTD
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Yunnan Botanee Bio-Technology Group Co.LTD

Aktien

300957

CNE100004G74

300957

Schlusskurs Shenzhen S.E.
Andere Börsenplätze
 00:00:00 14.05.2024 		% 5 Tage % 1. Jan.
59,23 CNY +1,91 % Intraday Chart für Yunnan Botanee Bio-Technology Group Co.LTD -3,96 % -13,11 %
29.04. YUNNAN BOTANEE BIO-TECHNOLOGY GROUP CO.LTD : Jefferies & Co. bekräftigt seine neutrale Bewertung ZM
25.04. Yunnan Botanee Bio-Technology Group Co.LTD meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Yunnan Botanee Bio-Technology Group Co.LTD Proposes Final Dividend for 2023
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the First Quarter Ended March 31, 2024
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Full Year Ended December 31, 2023
Tranche Update on Yunnan Botanee Bio-Technology Group Co.LTD's Equity Buyback Plan announced on August 30, 2023.
Certain A Shares of Yunnan Botanee Bio-Technology Group Co.LTD are subject to a Lock-Up Agreement Ending on 25-MAR-2024.
Weimai Medical Technology Co., Ltd. announced that it has received funding from CDH Investment Management Company Limited, Yunnan Botanee Bio-Technology Group Co.LTD
Weimai Qingtong Medical Technology Co., Ltd. announced that it has received funding from CDH Investment Management Company Limited, Changzhou Lizhong Investment Management Co., Ltd., Yunnan Botanee Bio-Technology Group Co.LTD, Guangdong Evergreen Conglomerate Co., Ltd.
Tranche Update on Yunnan Botanee Bio-Technology Group Co.LTD's Equity Buyback Plan announced on August 30, 2023.
In China's slowing beauty market, big brand discounts won't cut it
Shanghai Weimu Medical Technology Co., Ltd. announced that it has received CNY 100 million in funding from Yunnan Botanee Bio-Technology Group Co.LTD, Huajin Avenue Investment Co., Ltd., SHAREWIN Equity Investment and Management Co., Ltd., Shanghai CS Capital Co., Ltd, Sinvo Capital Holdings Co., Ltd., Investment Arm, IDG Capital Partners Co., Ltd.
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Nine Months Ended September 30, 2023
Yunnan Botanee Bio-Technology Group Co.LTD announces an Increase in Equity Buyback.
Weimai Medical Technology Co., Ltd. announced that it has received funding from Yunnan Botanee Bio-Technology Group Co.LTD
Yunnan Botanee Bio-Technology Group Co.LTD announces an Equity Buyback for CNY 200 million worth of its shares.
Yunnan Botanee Bio-Technology Group Co.LTD authorizes a Buyback Plan.
Yunnan Botanee’s H1 Profit Jumps 14% as Revenue Grows 15.5%
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Half Year Ended June 30, 2023
Shanghai Ruishi Health Technology Co., Ltd. announced that it has received CNY 100 million in funding from BRV Partners, LLC, Yaojin Private Equity Fund Management Co., Ltd., Sinovation Ventures Enterprise Management Limited, Yunnan Botanee Bio-Technology Group Co.LTD
Yunnan Botanee Seeks to Double Revenue in Three Years
Yunnan Botanee Bio-Technology Group Co.LTD Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 30 May 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 300957 Aktie
  4. Nachrichten Yunnan Botanee Bio-Technology Group Co.LTD
  5. Andere Sprachen